Literature DB >> 18677408

Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.

David S Ziegler1, Renee D Wright, Santosh Kesari, Madeleine E Lemieux, Mary A Tran, Monish Jain, Leigh Zawel, Andrew L Kung.   

Abstract

Multiple receptor tyrosine kinases (RTKs), including PDGFR, have been validated as therapeutic targets in glioblastoma multiforme (GBM), yet inhibitors of RTKs have had limited clinical success. As various antiapoptotic mechanisms render GBM cells resistant to chemo- and radiotherapy, we hypothesized that these antiapoptotic mechanisms also confer resistance to RTK inhibition. We found that in vitro inhibition of PDGFR in human GBM cells initiated the intrinsic pathway of apoptosis, as evidenced by mitochondrial outer membrane permeabilization, but downstream caspase activation was blocked by inhibitor of apoptosis proteins (IAPs). Consistent with this, inhibition of PDGFR combined with small molecule inactivation of IAPs induced apoptosis in human GBM cells in vitro and had synergistic antitumor effects in orthotopic mouse models of GBM and in primary human GBM neurospheres. These results demonstrate that concomitant inhibition of IAPs can overcome resistance to RTK inhibitors in human malignant GBM cells, and suggest that blockade of IAPs has the potential to improve treatment outcomes in patients with GBM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677408      PMCID: PMC2491457          DOI: 10.1172/JCI34120

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

Review 1.  Brain tumors.

Authors:  L M DeAngelis
Journal:  N Engl J Med       Date:  2001-01-11       Impact factor: 91.245

Review 2.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery.

Authors:  D R Groothuis
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

3.  Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma.

Authors:  B Wagenknecht; T Glaser; U Naumann; S Kügler; S Isenmann; M Bähr; R Korneluk; P Liston; M Weller
Journal:  Cell Death Differ       Date:  1999-04       Impact factor: 15.828

4.  Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.

Authors:  Tiziana Servidei; Anna Riccardi; Maurizio Sanguinetti; Carlo Dominici; Riccardo Riccardi
Journal:  J Cell Physiol       Date:  2006-07       Impact factor: 6.384

5.  Apoptosis repressor with caspase recruitment domain (ARC) is expressed in cancer cells and localizes to nuclei.

Authors:  Mi Wang; Suparna Qanungo; Michael T Crow; Michiko Watanabe; Anna-Liisa Nieminen
Journal:  FEBS Lett       Date:  2005-04-25       Impact factor: 4.124

Review 6.  Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor.

Authors:  E Ramsay Camp; Justin Summy; Todd W Bauer; Wenbiao Liu; Gary E Gallick; Lee M Ellis
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

Review 7.  Recent advances in the molecular genetics of primary gliomas.

Authors:  Gaspar J Kitange; Kristen L Templeton; Robert B Jenkins
Journal:  Curr Opin Oncol       Date:  2003-05       Impact factor: 3.645

8.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Authors:  James E Vince; W Wei-Lynn Wong; Nufail Khan; Rebecca Feltham; Diep Chau; Afsar U Ahmed; Christopher A Benetatos; Srinivas K Chunduru; Stephen M Condon; Mark McKinlay; Robert Brink; Martin Leverkus; Vinay Tergaonkar; Pascal Schneider; Bernard A Callus; Frank Koentgen; David L Vaux; John Silke
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

9.  Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells.

Authors:  S M Shamah; C D Stiles; A Guha
Journal:  Mol Cell Biol       Date:  1993-12       Impact factor: 4.272

10.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

View more
  50 in total

Review 1.  The regulatory crosstalk between kinases and proteases in cancer.

Authors:  Carlos López-Otín; Tony Hunter
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

2.  Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML.

Authors:  Bing Z Carter; Yi Hua Qiu; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Deborah A Thomas; Farhad Ravandi; Hagop M Kantarjian; Erich Koller; Michael Andreeff; Steven M Kornblau
Journal:  Blood       Date:  2010-11-01       Impact factor: 22.113

Review 3.  Insights into molecular therapy of glioma: current challenges and next generation blueprint.

Authors:  Y Rajesh; Ipsita Pal; Payel Banik; Sandipan Chakraborty; Sachin A Borkar; Goutam Dey; Ahona Mukherjee; Mahitosh Mandal
Journal:  Acta Pharmacol Sin       Date:  2017-03-20       Impact factor: 6.150

4.  A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.

Authors:  David S Ziegler; Joanna Keating; Santosh Kesari; Eva M Fast; Leigh Zawel; Naren Ramakrishna; Jessica Barnes; Mark W Kieran; Sophie E M Veldhuijzen van Zanten; Andrew L Kung
Journal:  Neuro Oncol       Date:  2011-07-01       Impact factor: 12.300

5.  Simultaneous reconstruction of multiple signaling pathways via the prize-collecting steiner forest problem.

Authors:  Nurcan Tuncbag; Alfredo Braunstein; Andrea Pagnani; Shao-Shan Carol Huang; Jennifer Chayes; Christian Borgs; Riccardo Zecchina; Ernest Fraenkel
Journal:  J Comput Biol       Date:  2013-02       Impact factor: 1.479

Review 6.  Small-molecule SMAC mimetics as new cancer therapeutics.

Authors:  Longchuan Bai; David C Smith; Shaomeng Wang
Journal:  Pharmacol Ther       Date:  2014-05-16       Impact factor: 12.310

7.  LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling.

Authors:  Longchuan Bai; Donna McEachern; Chao-Yie Yang; Jianfeng Lu; Haiying Sun; Shaomeng Wang
Journal:  Cancer Res       Date:  2012-01-12       Impact factor: 12.701

8.  Calanquinone A induces anti-glioblastoma activity through glutathione-involved DNA damage and AMPK activation.

Authors:  Fan-Lun Liu; Jui-Ling Hsu; Yean-Jang Lee; Yu-Shun Dong; Fan-Lu Kung; Ching-Shih Chen; Jih-Hwa Guh
Journal:  Eur J Pharmacol       Date:  2014-03-06       Impact factor: 4.432

9.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Authors:  Fiona M Foster; Thomas W Owens; Jolanta Tanianis-Hughes; Robert B Clarke; Keith Brennan; Nigel J Bundred; Charles H Streuli
Journal:  Breast Cancer Res       Date:  2009-06-29       Impact factor: 6.466

Review 10.  Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper.

Authors:  Lara Driggers; Jian-Gang Zhang; Elizabeth W Newcomb; Lisheng Ge; Neil Hoa; Martin R Jadus
Journal:  J Neurooncol       Date:  2009-10-04       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.